Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre‐treated with newer P2Y12 inhibitors

Objectives We sought to investigate the safety and potential benefit of administrating glycoprotein IIb‐IIIa inhibitors (GPIs) on top of more potent P2Y12 inhibitors. Background A number of clinical trials, performed at a time when pretreatment and potent platelet inhibition was not part of routine...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cardiology (Mahwah, N.J.) N.J.), 2021-08, Vol.44 (8), p.1080-1088
Main Authors: Blanchart, Katrien, Heudel, Thibaut, Ardouin, Pierre, Lemaitre, Adrien, Briet, Clément, Bignon, Mathieu, Sabatier, Rémi, Legallois, Damien, Roule, Vincent, Beygui, Farzin
Format: Article
Language:English
Subjects:
acute coronary syndrome
Acute coronary syndromes
Aggregation
Angioplasty
Anticoagulants
Blood clots
Blood platelets
Blood pressure
Cardiac patients
Care and treatment
Clinical Investigations
glycoprotein IIb/IIIa inhibitors
Glycoproteins
Health aspects
Heart attack
Heart attacks
Humans
Medical imaging
Medical research
Medicine, Experimental
Mortality
P2Y12 inhibitors
Patients
Percutaneous Coronary Intervention - adverse effects
Platelet Aggregation Inhibitors - adverse effects
Platelet Glycoprotein GPIIb-IIIa Complex
Population
prasugrel
Prospective Studies
Shock
ST Elevation Myocardial Infarction - diagnosis
ST Elevation Myocardial Infarction - therapy
ST segment elevation myocardial infarction
Stents
Thrombosis
ticagrelor
Transluminal angioplasty
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives We sought to investigate the safety and potential benefit of administrating glycoprotein IIb‐IIIa inhibitors (GPIs) on top of more potent P2Y12 inhibitors. Background A number of clinical trials, performed at a time when pretreatment and potent platelet inhibition was not part of routine clinical practice, have documented clinical benefits of GPI in ST‐segment elevation myocardial infarction (STEMI) patients at the cost of a higher risk of bleeding. Methods We used the data of a prospective, ongoing registry of patients admitted for STEMI in our center. For the purpose of this study only patients presenting for primary percutaneous coronary intervention and pretreated with new P2Y12 inhibitors (prasugrel or ticagrelor) were included. We compared patients who received GPI with those who did not. Results Eight hundred twenty‐four STEMI patients were included in our registry; GPIs were used in 338 patients (41%). GPI patients presented more often with cardiogenic shock and Thrombolysis in myocardial infarction (TIMI) flow grade
ISSN:0160-9289
1932-8737
1932-8737
DOI:10.1002/clc.23654